β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer
β-glucan combined with Envafolimab and Endostar has considerable efficacy and safety for immune rechallenge in metastatic NSCLC patients who failed of anti-PD-1 treatment previously, especially for PD-L1 positive patients.
Authors
- Chunjian Qi (ORCID: https://orcid.org/0000-0001-9567-112X)
- Hua Jiang (ORCID: https://orcid.org/0000-0002-4552-0785)
- Quanbin Zha (ORCID: https://orcid.org/0000-0003-0949-3350)
- Lanqun Qin
- Ge Wang (ORCID: https://orcid.org/0000-0002-2656-7705)
- Dongqing Li (ORCID: https://orcid.org/0000-0001-8724-0944)
- Xiaolin Pu
- Yingying Lu (ORCID: https://orcid.org/0000-0002-7187-1511)
- Yi Zhuang (ORCID: https://orcid.org/0000-0001-7740-7317)
- Yajun Emily Zhu
- Qian Geng (ORCID: https://orcid.org/0000-0003-2351-5042)
Institutions
- Jiangsu University (CN)
- Soochow University (CN)
- Jintan People's Hospital (CN)
- Hangzhou Hospital of Traditional Chinese Medicine (CN)
- Changzhou No.2 People's Hospital (CN)
- Changzhou University (CN)
- Fourth People's Hospital of Changzhou (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Immunology
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1186/s12865-024-00651-x
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Nanjing Medical University